Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TUB-040

Antibody-drug conjugate · Cytotoxic, directed at sodium-dependent phosphate transport protein 2B (SLC34A2) · developed by Gilead Sciences

Phase 1/2 Most advanced trial

GILD Developer

1 Registered trials

What is TUB-040?

TUB-040 is an antibody-drug conjugate composed of a humanized IgG1 antibody against SLC34A2 conjugated to exatecan, a topoisomerase 1 inhibitor. The antibody binds SLC34A2 on tumor cells, enabling cellular uptake and release of exatecan, which inhibits DNA topoisomerase I and induces apoptosis. It is studied in ovarian and non-small cell lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: sodium-dependent phosphate transport protein 2B (SLC34A2), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at sodium-dependent phosphate transport protein 2B (SLC34A2)
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: Gilead Sciences (GILD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06303505	Phase 1/2	Ovarian Cancer	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung CancerOvarian Cancer

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind TUB-040

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z